NR4A1 and breast carcinoma: The GenesWell Breast Cancer Test (BCT) (Gencurix, Inc., Seoul, Korea) is a molecular prognostic assay that predicts the risk of 10–year distant metastasis in patients with pathologic N0 or N1 status (pN0-N1), hormone receptor-positive, HER2-negative breast cancer (26).